IP Library Granted Patent US 7,771,999
Granted Patent B2
US 7,771,999 · App. 12/047,107 · Granted Aug 10, 2010

Disease model incorporation into an artificial immune system (AIS)

Assignee: VaxDesign Corp.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,771,999
App. No.
12/047,107
Granted
Aug 10, 2010
Kind
B2
Abstract

The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the tissues of the immune system in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates and other materials in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interactions with the immune system, coupled with disease models to provide a more complete representation of an immune response.

Claims (23)

1. An in vitro two culture cellular system comprising:

a culture of a two- or three-dimensional matrix, comprising lymphoid tissue; and

a culture of diseased cells, wherein said diseased cells are immune system cells, selected from the group consisting of PBMCs, monocytes, macrophages, dendritic cells, lymphocytes, and antigen-presenting cells.

2. The in vitro system of claim 1 , wherein said diseased cells are selected from the group consisting of virally infected cells, bacterially infected cells, tumor cells, and autoimmune disease-afflicted cells.

3. The in vitro system of claim 1 , wherein said diseased cells are virally infected cells.

4. The in vitro system of claim 1 , wherein said diseased cells are bacterially infected cells.

5. The in vitro system of claim 1 , wherein said diseased cells comprise PBMCs derived from blood donors infected with a virus.

6. The in vitro system of claim 1 , wherein said diseased cells comprise PBMCs derived from uninfected blood donors, and wherein said PBMCs are in vitro with a virus.

7. The in vitro system of claim 1 , wherein said diseased cells comprise PBMCs derived from blood donors infected with a bacterium.

8. The in vitro system of claim 1 , wherein said diseased cells comprise PBMCs derived from blood donors afflicted with an autoimmune disease.

9. The in vitro system of claim 1 , wherein said diseased cells comprise PBMCs derived from uninfected blood donors, and wherein said PBMCs are infected in vitro with a bacterium.

10. An in vitro three culture cellular system comprising:

a culture of a two- or three-dimensional matrix, comprising lymphoid tissue;

a culture of a two- or three-dimensional matrix, comprising epithelial and/or endothelial cells; and

a culture of diseased cells, wherein said diseased cells are immune system cells, selected from the group consisting of PBMCs, monocytes, macrophages, dendritic cells, lymphocytes, and antigen-presenting cells.

11. The in vitro system of claim 10 , wherein said diseased cells are selected from the group consisting of virally infected cells, bacterially infected cells, tumor cells, and autoimmune disease-afflicted cells.

12. The in vitro system of claim 10 , wherein said diseased cells are virally infected cells.

13. The in vitro system of claim 10 , wherein said diseased cells are bacterially infected cells.

14. The in vitro system of claim 10 , wherein said diseased cells comprise PBMCs derived from blood donors infected with a virus.

15. The in vitro system of claim 10 , wherein said diseased cells comprise PBMCs derived from uninfected blood donors, and wherein said PBMCs are infected in vitro with a virus.

16. The in vitro system of claim 10 , wherein said diseased cells comprise PBMCs derived from blood donors infected with a bacterium.

17. The in vitro system of claim 10 , wherein said diseased cells comprise PBMCs derived from blood donors afflicted with an autoimmune disease.

18. The in vitro system of claim 10 , wherein said diseased cells comprise PBMCs derived from uninfected blood donors, and wherein said PBMCs are infected in vitro with a bacterium.

Assignments (2)
MERGER Recorded Jun 2, 2011
From: VAXDESIGN CORPORTATION
To: SANOFI PASTEUR VAXDESIGN CORPORATION
Reel/Frame 026377/0649 →
NUNC PRO TUNC ASSIGNMENT EFFECTIVE DATE: 03/12/2008. Recorded Feb 1, 2010
From: WARREN, WILLIAM L.; FAHLENKAMP, HEATHER; HIGBEE, RUSSELL; MISHKIN, ERIC; RIVARD, MICHAEL; PAWAR, SANTOSH; SANCHEZ-SCHMITZ, GUZMAN
To: VAXDESIGN CORP.
Reel/Frame 023877/0071 →
Continuity (5)
Continuation In Part 1145300300 · Jun 15, 2006
Continuation In Part 1111623400 · Apr 28, 2005
Provisional Application 6056584600 · Apr 28, 2004
Provisional Application 6064317500 · Jan 13, 2005
Related Publication 20090011455A1 · Jan 8, 2009